What this means
Partial reprogramming by cyclic expression of Yamanaka factors has been proposed as a rejuvenation strategy, yet evaluating tissue-specific responses and potential risks remains challenging. Here, we reanalyzed RNA-seq data from the liver, kidney, and spleen of aged mice subjected to seven months of partial reprogramming.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- Animals or cells
- Kind of research
- Research in animals or cells
The science
- Original title
- Investigating the efficacy and toxicity of partial in vivo reprogramming as a rejuvenation intervention.
- Authors
- Meiners F, Palmer D, Avelar RA et al.
- Journal
- Aging
- Published
- Oct 29, 2026
- Study type
- Lab or animal study · indexed as animal research
- PMID
- 42954813 ↗
Abstract
Partial reprogramming by cyclic expression of Yamanaka factors has been proposed as a rejuvenation strategy, yet evaluating tissue-specific responses and potential risks remains challenging. Here, we reanalyzed RNA-seq data from the liver, kidney, and spleen of aged mice subjected to seven months of partial reprogramming. We used the Adverse Outcome Pathway (AOP) framework to estimate adverse and beneficial signatures, assessed functional changes via gene set enrichment analysis and deconvoluted bulk RNA-seq data to estimate differences in cell type proportion. In the liver and kidney, partial reprogramming suppressed age-activated immune and inflammatory processes, while activating age-suppressed metabolic and catabolic pathways. In the spleen, cell cycle, DNA replication, and DNA damage response programs were prominent, indicative of increased proliferative activity, and cell type deconvolution showed increased proportions of megakaryocyte-erythroid progenitor cells and decreased proportions of natural killer cells, while AOPs flagged a potential risk of sustained genomic and proliferative stress. Based on the existing AOP framework, we did not find any enriched Key Events in the kidney (reprogrammed vs. old). In the liver, AOP analysis identified pathways regulated in opposition to liver steatosis, indicated by activation of nuclear receptor signaling (Ppara, Pparg) and restoration of fatty-acid oxidation and metabolism. Our findings highlight tissue-specific responses to partial reprogramming and emphasize the need for larger, controlled studies to clarify physiological outcomes and safety.
Meiners F, Palmer D, Avelar RA et al. Investigating the efficacy and toxicity of partial in vivo reprogramming as a rejuvenation intervention. Aging. 2026. doi:10.18632/aging.206431. PMID: 42954813. https://pubmed.ncbi.nlm.nih.gov/42954813/
Related research
Partial reprogramming in aged mice reduced brain damage after a stroke-like event
Researchers turned on four reprogramming genes in older mice and then blocked a brain artery. Those mice had smaller brain damage and better movement than normal mice.
A new idea about how body-wide signals may speed up aging late in life
This paper proposes a theory that signals between cells across the body shape how fast aging speeds up. It is an idea, not a tested result, so it does not prove the theory is right.
Plant extracts studied for effects on aging skin cells in a preprint
Researchers tested plant extract mixes on aged skin cells and skin samples in a lab. This is an early preprint, not yet checked by other scientists, so it does not show these mixes help real skin.
Gene SRSF1 slowed signs of aging in cells and in older mice
Scientists boosted one gene in aged human cells and in mice. It made the cells and mice look younger in some ways. This does not show it would work the same way in people.
See all research on Cell reprogramming (Yamanaka factors) →